Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.
Manley BJ, Kamlin COF, Donath SM, Francis KL, Cheong JLY, Dargaville PA, Dawson JA, Jacobs SE, Birch P, Resnick SM, Schmölzer GM, Law B, Bhatia R, Bach KP, de Waal K, Travadi JN, Koorts PJ, Berry MJ, Lui K, Rajadurai VS, Chandran S, Kluckow M, Cloete E, Broom MM, Stark MJ, Gordon A, Kodur V, Doyle LW, Davis PG, McKinlay CJD; PLUSS Trial Investigators. Manley BJ, et al. JAMA. 2024 Nov 11:e2417380. doi: 10.1001/jama.2024.17380. Online ahead of print. JAMA. 2024. PMID: 39527075
The political stakes of cancer epistemics.
Bhangu S, Argudo-Portal V, Araújo Neto LA, Cochrane T, Denisova M, Surawy-Stepney N. Bhangu S, et al. Among authors: cochrane t. Soc Sci Med. 2024 Oct;359:117176. doi: 10.1016/j.socscimed.2024.117176. Epub 2024 Aug 2. Soc Sci Med. 2024. PMID: 39244964 Free article.
Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study.
Verner E, Johnston A, Pati N, Hawkes EA, Lee HP, Cochrane T, Cheah CY, Filshie R, Purtill D, Sia H, Enjeti AK, Brown C, Murphy N, Curnow J, Lee K, Gandhi MK, Walia M, Butcher BE, Trotman J. Verner E, et al. Among authors: cochrane t. Blood Adv. 2024 Nov 12;8(21):5674-5682. doi: 10.1182/bloodadvances.2024014035. Blood Adv. 2024. PMID: 39226464 Free PMC article. Clinical Trial.
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.
Tatarczuch M, Lewis KL, Gunjur A, Shaw B, Poon LM, Paul E, Ku M, Wong M, Ai S, Beekman A, Ciaccio PRD, Krigstein M, Wight J, Coombes C, Gilbertson M, Tey A, Shortt J, Nagarajan C, Talaulikar D, Hamad N, Ratnasingam S, Ho SJ, Cochrane T, Hawkes EA, Cheah CY, Opat S, Gregory GP. Tatarczuch M, et al. Among authors: cochrane t. EJHaem. 2024 Jun 21;5(4):709-720. doi: 10.1002/jha2.951. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157596 Free PMC article.
Care biography: A concept analysis.
Tieu M, Cussó RA, Collier A, Cochrane T, Pinero de Plaza MA, Lawless M, Feo R, Perimal-Lewis L, Thamm C, Hendriks JM, Lee J, George S, Laver K, Kitson A. Tieu M, et al. Among authors: cochrane t. Nurs Philos. 2024 Jul;25(3):e12489. doi: 10.1111/nup.12489. Nurs Philos. 2024. PMID: 38993083
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.
Baggio D, Chung E, Wellard C, Waters N, Cushion T, Chong G, Cochrane T, Cull G, Giri P, Hamad N, Johnston A, Lee D, Murali A, Morgan S, Mulligan S, Talaulikar D, Ratnasingam S, Wood E, Hawkes E, Opat S. Baggio D, et al. Among authors: cochrane t. Intern Med J. 2024 Jul;54(7):1223-1227. doi: 10.1111/imj.16445. Epub 2024 Jul 7. Intern Med J. 2024. PMID: 38973146
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.
Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, Christensen JH, Hess B, Tilly H, Cordoba R, Lewis DJ, Okada C, Hutchings M, Clausen MR, Sancho JM, Cochrane T, Leppä S, Chamuleau MED, Gernhardt D, Altıntaş I, Liu Y, Ahmadi T, Dinh MH, Hoehn D, Favaro E, Elliott B, Thieblemont C, Vose JM. Linton KM, et al. Among authors: cochrane t. Lancet Haematol. 2024 Aug;11(8):e593-e605. doi: 10.1016/S2352-3026(24)00166-2. Epub 2024 Jun 15. Lancet Haematol. 2024. PMID: 38889737 Clinical Trial.
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.
Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs S, Lee S, Lee E, Taylor K, Cochrane T, Wallington-Gates C, Kwok F, Weber N, Kerridge I, Weston H, Ho PJ, Leahy MF, Horvath N, Spencer A. Mollee P, et al. Among authors: cochrane t. Blood Adv. 2024 Jul 23;8(14):3721-3730. doi: 10.1182/bloodadvances.2023012539. Blood Adv. 2024. PMID: 38739707 Free PMC article. Clinical Trial.
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Shaw B, Chung E, Wellard C, Yoo E, Bennett R, Birks C, Johnston A, Cheah CY, Hamad N, Simpson J, Barraclough A, Ku M, Viiala N, Ratnasingam S, Armytage T, Cochrane T, Chong G, Lee D, Manos K, Keane C, Wallwork S, Opat S, Hawkes EA. Shaw B, et al. Among authors: cochrane t. EJHaem. 2024 Feb 23;5(2):325-332. doi: 10.1002/jha2.870. eCollection 2024 Apr. EJHaem. 2024. PMID: 38633125 Free PMC article.
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
Manos K, Churilov L, Grigg A, Di Ciaccio P, Wong J, Chandra Sekaran U, Wight J, Goh Z, Jina H, Butler L, Yannakou CK, Hamad N, Gregory GP, Gangatharan S, Cochrane T, Hawkes EA, Lasica M. Manos K, et al. Among authors: cochrane t. Br J Haematol. 2024 Jul;205(1):146-157. doi: 10.1111/bjh.19407. Epub 2024 Mar 14. Br J Haematol. 2024. PMID: 38485116
244 results